New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
08:09 EDTNEPTNeptune Technologies obtains third U.S. patent on phospholipid compositions
Neptune Technologies & Bioressources announces that the U.S. Patent & Trademark has granted to Neptune a new continuation patent, U.S. Patent 8,383,675. This new patent claims the benefit of prior Neptune U.S. Patent Nos. 8,030,348 and 8,278,351. The '675 Patent contains a single claim directed to a capsule comprising an Antarctic krill oil extract comprising a phospholipid suitable for human consumption. This claim covers most, if not all, krill oil products presently sold in the U.S. market, as well as the pharmaceutical concentrates of Neptune's subsidiaries Acasti Pharma and NeuroBioPharm. Henri Harland, president and CEO of Neptune, commented; "This is not 'just another patent for Neptune.' It is part of Neptune's IP strategy, and it reinforces Neptune's continual effort to build its patent portfolio and defend its rights. Neptune's recent filing of a complaint with the United States International Trade Commission, as well as the issuance of this third composition patent in the United States, are part of Neptune's well thought and ongoing IP action plan."
News For NEPT From The Last 14 Days
Check below for free stories on NEPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
14:05 EDTNEPTNeptune says '348 patent still valid, to appeal USPTO decision
Neptune Technologies & Bioressources (NEPT) announced that the United States Patent and Trademark Office, or USPTO, recently issued a Right of Appeal Notice in an inter partes reexamination of Neptune's '348 patent. Despite the USPTO's decision, the '348 patent is still valid as Neptune has the right to appeal, which it intends to do, the company said. "Enzymotec (ENZY), in yet another clear attempt to shift focus from the on-going International Trade Commission investigation of its infringement of other Neptune patents, issued a press release addressing the '348 Patent decision. However, Enzymotec failed to highlight that the decision has no impact on the ITC investigation into infringement of Neptune's other composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Furthermore, the decision has no impact on Neptune's license agreements with Rimfrost and Aker BioMarine," said Neptune.
08:09 EDTNEPTEnzymotec says USPTO issues final decision, rejects all claims in Neptune patent
Subscribe for More Information
April 10, 2014
16:09 EDTNEPTGeorge Haywood reports 9.9% stake in Neptune Technologies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use